MetLife Investment Management’s Kalaris Therapeutics, Inc. Common Stock KLRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-927
| Closed | -$45.8K | – | 2870 |
|
|
2023
Q3 | $45.8K | Hold |
927
| – | – | ﹤0.01% | 2838 |
|
|
2023
Q2 | $72.5K | Buy |
927
+200
| +28% | +$15.6K | ﹤0.01% | 2839 |
|
|
2023
Q1 | $65.8K | Hold |
727
| – | – | ﹤0.01% | 2684 |
|
|
2022
Q4 | $85.7K | Hold |
727
| – | – | ﹤0.01% | 2650 |
|
|
2022
Q3 | $132K | Buy |
+727
| New | +$132K | ﹤0.01% | 2541 |
|
|
2022
Q2 | – | Sell |
-785
| Closed | -$122K | – | 2915 |
|
|
2022
Q1 | $122K | Buy |
785
+267
| +52% | +$41.4K | ﹤0.01% | 2587 |
|
|
2021
Q4 | $154K | Hold |
518
| – | – | ﹤0.01% | 2212 |
|
|
2021
Q3 | $299K | Hold |
518
| – | – | ﹤0.01% | 1823 |
|
|
2021
Q2 | $235K | Hold |
518
| – | – | ﹤0.01% | 2050 |
|
|
2021
Q1 | $279K | Buy |
518
+169
| +48% | +$91K | ﹤0.01% | 1858 |
|
|
2020
Q4 | $308K | Hold |
349
| – | – | ﹤0.01% | 1755 |
|
|
2020
Q3 | $221K | Buy |
+349
| New | +$221K | ﹤0.01% | 1803 |
|